David Kamenir serves as the Vice President of North America Enterprise Strategy and Business Development at Novo Nordisk, where they have contributed over 20 years to driving company strategy and operations. They successfully led the transition from a focus on insulin to a GLP1a-based portfolio, facilitating the launch of notable products like Ozempic® and Wegovy®. Throughout their career, Kamenir has been instrumental in building high-performing teams and fostering a culture of innovation that has significantly expanded patient reach. Their previous roles included Senior Director of Executive Operations and various strategic leadership positions within Novo Nordisk, as well as experience in CPG consulting at Information Resources, Inc. Kamenir is currently furthering their education with an MBA at the Fox School of Business and other executive programs.
This person is not in any teams
This person is not in any offices